Last reviewed 2026-05-14 · How we verify

Cytosin-Arabinosid

Cytarabine (Cytosin-Arabinosid) is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA during the S phase of the cell cycle, leading to cell death.

Cytarabine (Cytosin-Arabinosid) is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA during the S phase of the cell cycle, leading to cell death. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast phase.

At a glance

Mechanism of action

Cytarabine is a cytidine analog that is phosphorylated intracellularly and incorporated into DNA, causing chain termination and inhibition of DNA polymerase. This mechanism is particularly effective against rapidly dividing cells, making it useful in hematologic malignancies. It is cell cycle-specific, acting primarily during the S phase.

Approved indications

• Acute myeloid leukemia (AML)
• Acute lymphoblastic leukemia (ALL)
• Chronic myeloid leukemia (CML) in blast phase
• Lymphoma

Common side effects

• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Nausea and vomiting
• Mucositis
• Hepatotoxicity
• Neurotoxicity (at high doses)
• Fever

Key clinical trials

• Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Cytosin-Arabinosid CI brief — competitive landscape report
• Cytosin-Arabinosid updates RSS · CI watch RSS
• University of Ulm portfolio CI